open access

Vol 14, No 4 (2010)
Artykuły redakcyjne
Published online: 2010-10-14
Get Citation

Will new antihypertensive drugs emerge? Part 1

Anna Wolska-Bułach, Lucyna Woźnicka-Leśkiewicz, Jerzy Głuszek
Nadciśnienie tętnicze 2010;14(4):235-252.

open access

Vol 14, No 4 (2010)
Artykuły redakcyjne
Published online: 2010-10-14

Abstract

Even though there are numerous hypotensive preparations available on the market, the effectiveness of the therapy of arterial hypertension is still highly unsatisfactory. The effectiveness of the therapy would certainly be enhanced by the introduction of new antihypertensive drugs. Our work outlines currently-studied pathophysiological mechanisms, knowledge of which may improve synthesis and introduce new hypotensive drugs into the pharmaceutical market. We further describe innovative chemical compounds that have a chance to expand the pharmacological potential of the arterial hypertension therapy in the near future. In particular, the research briefly presents compounds that demonstrate the agonist-like activity to angiotensin 1–7, inhibiting biosynthesis or blocking endothelin receptors and inhibitors of the cerebral aminopeptidase and vascular oxidase. Finally the research introduces new preparations that open the potassium channel and release nitric oxide. The second part of the work briefly outlines the study of the compounds demonstrating a simultaneous effect on two metabolic pathways leading to the reduction of blood pressure. For example, preparations that have a simultaneous effect on both, the angiotensin converting enzyme and the natriuretic peptide synthesis, or drugs from the calcium antagonists group, which inhibit both the L-type and T-type calcium channels. The described preparations are at different stages of the pharmacological and clinical studies; however, it may be expected that at least some of them will be applied in the therapy of arterial hypertension in the relatively near future.
Arterial Hypertension 2010, vol. 14, no 4, pages 235-252.

Abstract

Even though there are numerous hypotensive preparations available on the market, the effectiveness of the therapy of arterial hypertension is still highly unsatisfactory. The effectiveness of the therapy would certainly be enhanced by the introduction of new antihypertensive drugs. Our work outlines currently-studied pathophysiological mechanisms, knowledge of which may improve synthesis and introduce new hypotensive drugs into the pharmaceutical market. We further describe innovative chemical compounds that have a chance to expand the pharmacological potential of the arterial hypertension therapy in the near future. In particular, the research briefly presents compounds that demonstrate the agonist-like activity to angiotensin 1–7, inhibiting biosynthesis or blocking endothelin receptors and inhibitors of the cerebral aminopeptidase and vascular oxidase. Finally the research introduces new preparations that open the potassium channel and release nitric oxide. The second part of the work briefly outlines the study of the compounds demonstrating a simultaneous effect on two metabolic pathways leading to the reduction of blood pressure. For example, preparations that have a simultaneous effect on both, the angiotensin converting enzyme and the natriuretic peptide synthesis, or drugs from the calcium antagonists group, which inhibit both the L-type and T-type calcium channels. The described preparations are at different stages of the pharmacological and clinical studies; however, it may be expected that at least some of them will be applied in the therapy of arterial hypertension in the relatively near future.
Arterial Hypertension 2010, vol. 14, no 4, pages 235-252.
Get Citation

Keywords

hypertension; MAS receptor; ETA receptor; AT1 receptor; angiotensin 1–7; multi-target drugs; ACE; ECE; NEP; nitric oxide releasing drug

About this article
Title

Will new antihypertensive drugs emerge? Part 1

Journal

Arterial Hypertension

Issue

Vol 14, No 4 (2010)

Pages

235-252

Published online

2010-10-14

Bibliographic record

Nadciśnienie tętnicze 2010;14(4):235-252.

Keywords

hypertension
MAS receptor
ETA receptor
AT1 receptor
angiotensin 1–7
multi-target drugs
ACE
ECE
NEP
nitric oxide releasing drug

Authors

Anna Wolska-Bułach
Lucyna Woźnicka-Leśkiewicz
Jerzy Głuszek

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl